AHPPI Annual Meeting
Friday 22 June, 09.00 – 17.00
Church House, Westminster, London
We are pleased to present the programme for this year’s AHPPI Annual Meeting.
Programme
| 09:00 | Arrival and Coffee | |
| 09:30 | Welcome and opening remarks | AHPPI |
| Morning Session | Chaired by Prof James Ritter, Emeritus Professor of Clinical Pharmacology, Kings College London | |
| 09.45 | Keynote speech | Professor Alan Boyd, President of the Faculty of Pharmaceutical Medicine |
| 10.25 | Integrating adaptive pharmaceutical and clinical strategies to improve flexibility and efficiency in early development. | Prof Peter Scholes, Chief Scientific Officer, Quotient Sciences |
| 11:05 | Tea/Coffee & Networking | |
| 11:35 | Medical Imaging in early Phase Trials | Dr Phillip Murphy; Head, Clinical Imaging, GlaxoSmithkline |
| 12:15 | The impact of the Revised EMA FIH guidelines on toxicity assessment and dose escalation | Dr David Jones, Expert Pharmaco-Toxicologist, Clinical Trials Unit, MHRA |
| 12:55 | Lunch and networking | |
| Afternoon Session | Chaired by Dr Alan Houston, Vice President, European Head of Clinical Development at BioMarin Pharmaceutical Inc. | |
| 14:00 | Early trials in Patients | Charlotte Chadwick, Head of Early Phase Unit, MAC Research |
| 14:40 | Capitalising on our experience in the review of early phase clinical trials | Catherine Blewett, HRA Improvement and Liaison Manager, Health Research Authority |
| 15:20 | Tea/Coffee & Networking | |
| 15:50 | UK Clinical Trials Regulation – Challenges and Opportunities of the New CTR | Dr Sam Bunce, Leeds University |
| 16:30 | Brexit and beyond: Ensuring the UK remains a great place to conduct clinical trials | Dr Kirsty Wydenbach, Deputy Unit Manager / Senior Medical Assessor, Clinical Trials Unit, MHRA |
| 17:10 | Discussion and closing remarks | AHPPI |
The Faculty of Pharmaceutical Medicine has approved this event for CPD (6.5 points).
Please contact us with any questions at info@ahppi.org.uk
Frontiers in Pharmacology have kindly offered to publish the proceedings of this meeting.
Niche Science and Technology Limited will prepare the manuscript.
We were delighted to be sponsored by Celerion, Quotient Sciences, PAREXEL and Richmond Pharmacology for this year’s meeting.
